Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2019-03-28 Board/Management Inform…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Board changes
Board/Management Information Classification · 1% confidence The document explicitly announces changes to the company's board of directors: the appointment of Mark Breuer as Non-Executive Director and the stepping down of Meghan FitzGerald. This content directly aligns with the definition of Board/Management Information.
2019-03-28 English
Arix Bioscience Plc - Notice of Results
Report Publication Announcement Classification · 1% confidence The document is titled "Arix Bioscience Plc - Notice of Results" and explicitly states that the company "will announce its annual results for the year ended 31 December 2018 on Thursday, 28 March 2019." It also mentions a breakfast briefing/call for analysts. This text is not the full annual results (10-K) or the results themselves (ER/IR), but rather an announcement about *when* the results will be published. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published fits the description of a Report Publication Announcement (RPA).
2019-03-20 English
Arix Bioscience Plc - Arix co-leads $63m Series B investment round for Imara
Capital/Financing Update Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing its co-leadership in a $63 million Series B investment round for a portfolio company, Imara, Inc. This announcement details a financing activity, including the amount committed by Arix ($15.0 million) and the resulting ownership stake (10%). This clearly falls under the category of updates on company fundraising or capital structure changes. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release; it's a specific investment announcement. - CT/IP: Not a transcript or a general investor presentation. - CAP (Capital/Financing Update): This definition perfectly matches the content: "Updates on company fundraising, financing activities, or capital structure changes." Therefore, the classification is CAP.
2019-03-18 English
Arix Bioscience Plc - Autolus announces updated results from CARPALL trial
Earnings Release Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting that its portfolio company, Autolus Therapeutics, presented updated clinical trial data (CARPALL trial results) at a medical conference. This is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER) which typically contains summarized financial statements. It is an announcement of scientific/clinical data, which often falls under general investor relations communication. Since the content is a detailed update on clinical trial results and scientific progress, it is best classified as an Investor Presentation (IP) if it were a slide deck, but as a press release announcing data, it functions as a key piece of information for investors. Given the options, and recognizing that this is a detailed announcement of clinical data intended for investors, it most closely aligns with the spirit of an Investor Presentation (IP) or a general Regulatory Filing (RNS) if no better fit exists. However, since it is a detailed announcement of clinical results, and not just a brief notice of a report being available, it is more substantial than an RPA. It is a specific update on a product/trial, which is a core component of investor information. Given the detailed nature of the results (safety, efficacy, survival rates), it functions as a specialized investor update. If the document were a formal presentation deck, it would be IP. As a press release detailing these results, it is a significant piece of investor information. Since there is no specific 'Clinical Trial Update' code, and it is not a formal financial report, 'RNS' (Regulatory Filings/General Announcement) is the safest fallback, but 'IP' (Investor Presentation) often covers detailed non-financial updates presented to investors. Given the context of a press release detailing specific clinical data points, I will classify it as a general Regulatory Filing (RNS) as it is a PR distributed via PR Newswire, unless it is clearly a presentation document. Since it is a press release, RNS is the most appropriate general category for non-standard regulatory/investor announcements. Q1 2019
2019-02-19 English
Arix Bioscience Plc - Harpoon closes initial public offering
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Arix Bioscience's portfolio company, Harpoon Therapeutics, has closed its initial public offering (IPO). It details the offering size, price, gross proceeds, and Arix's resulting stake and gain. This type of announcement, detailing fundraising, capital structure changes, or significant investment outcomes for a portfolio company, aligns best with the 'Capital/Financing Update' category. It is not a formal regulatory report like a 10-K or IR, nor is it a general regulatory filing (RNS) since it fits a more specific category (CAP).
2019-02-14 English
Arix Bioscience Plc - Harpoon prices Nasdaq IPO
Regulatory Filings Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing that its portfolio company, Harpoon Therapeutics, has priced its Initial Public Offering (IPO) on Nasdaq. This announcement details Arix's investment, the resulting valuation uplift, and the expected trading date. This type of announcement, concerning fundraising, investment in another entity, and capital structure changes related to that investment, most closely aligns with the 'Capital/Financing Update' category. It is not a full 10-K, an earnings release (ER), or a standard regulatory filing (RNS) that lacks a specific category, as it is focused on a specific financing event.
2019-02-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.